BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Countries North America

Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...

November 10, 2026 | News

Vir Biotechnology’s Hepatitis Delta Combo Suppresses Virus to Undetectable Levels in All 28 Week 96 Completers

Data presented at AASLD The Liver Meeting demonstrated 100% of participants (28/28) who completed Week 96 of combination therapy reached undetectable v...

November 10, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

VS Pharmtech Advances Radiotherapy Enhancer VS-101 to Phase 2 in the US

Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anti...

November 09, 2026 | News

Differentia Bio Reports Clinical Support for AI-Predicted Treatment Strategies in IgG4-Related Disease

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharma...

November 05, 2026 | News

Lonza to Acquire Five US CDMO Sites from Merck KGaA to Double Manufacturing Footprint

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites wit...

November 04, 2026 | News

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

Enveda and Anthropic Cut Drug Batch Review Time by 89% Using Claude AI

In an internal evaluation, Claude-powered workflows reduced batch-record review time by 89% and produced a first draft of regulatory content in hours rat...

October 29, 2026 | News

Octant Secures FDA Orphan Drug Designation for OCT-980 to Treat Retinitis Pigmentosa

Octant, Inc. (“Octant”), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, announced that th...

October 29, 2026 | News

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

October 28, 2026 | Analysis

MEPSGEN Launches NanoCalibur Mini to Accelerate Nanoparticle Formulation for Drug Discovery

Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro...

October 28, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

Stay Connected